Green Cross to produce once-daily influenza treatment
Published: 2010-08-18 06:56:00
Updated: 2010-08-18 06:56:00
Green Cross Corp., a Korean drug firm, will market its investigational antiviral drug. Approval was given on August 15 by the Korea Food and Drug Administration (KFDA) for the sales of the intravenous antiviral named PeramiFlu.
Green Cross received the indication of single dose administration ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
